Skip to main content

Table 1 Patients’ Characteristics

From: Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe

  Overall
(N = 828)
Genotype-A
(N = 255)
Genotype-D
(N = 573)
P-valued
General
 Median Age (IQR), years 45 (38–59) 45 (33–56) 49 (40–59) 0.001
 Male, N(%)a 584 (70.5) 183 (74.4) 401 (73.6) 0.810
CHB-related data
 Median HBV-DNA, log IU/ml (IQR) 4.4 (3.2–6.4) 4.7(3.3–6.9) 4.4 (3.2–6.3) 0.079
 HBeAg positive, N(%)b 183 (44.1) 71 (59.7) 112 (38) < 0.001
 Median ALT, IU/L (IQR) 46.5 (32–78) 46 (30–80) 48 (32–78) 0.473
Geographical origin, N(%)
 Western Europe 142 (17.1) 67 (26.3) 75 (13.1) < 0.001
 Northern Europe 26 (3.1) 10 (3.9) 16 (2.8) 0.519
 Eastern Europe 131 (15.8) 99 (38.8) 32 (5.6) < 0.001
 Southern Europe 529 (63.9) 79 (31) 450 (78.5) < 0.001
Anti-HBV drug history, N(%)c
Monotherapy
  LAM 406 (62.5) 157 (66.8) 249 (60) 0.085
  ADV 32 (4.9) 10 (4.3) 22 (5.3) 0.554
  ETV 31 (4.8) 7 (3) 24 (5.8) 0.107
  TDF 5 (0.8) 2 (0.9) 3 (0.7) 0.857
  LdT 3 (0.5) 1 (0.4) 2 (0.5) 1.000
Dual exposure
  LAM + ADV 115 (17.7) 27 (11.5) 88 (21.2) 0.002
  LAM + TDF 21 (3.2) 14 (6) 7 (1.7) 0.003
  LAM + ETV 17 (2.6) 10 (4.3) 7 (1.7) 0.045
  ADV + ETV 4 (0.6) 3 (1.3) 1 (0.2) 0.137
  ETV + TDF 3 (0.5) 3 (1.3) 0 (0) 0.047
  ADV + ETV 1 (0.2) 0 (0) 1 (0.2) 1.000
Triple exposure
  LAM + ADV + ETV 5 (0.8) 1 (0.4) 4 (1) 0.450
  LAM + ADV + TDF 7 (1.1) 0 (0) 7 (1.7) 0.045
  1. a Percentages are calculated on 791 patients with the datum available, 246 patients for genotype A and 545 for genotype D
  2. b Percentages are calculated on 414 patients with the datum available, 119 patients for genotype A and 295 for genotype D
  3. c Percentages are calculated on 650 patients with the type of anti-HBV drugs available, 235 patients for genotype A and 415 for genotype D
  4. d Statistically significant difference was assessed by Chi-squared Test based on a 2 × 2 contingency table
  5. P-value in italic are statistically significant
  6. Abbreviations: ADV adefovir, ETV entecavir, IQR interquartile range, LAM lamivudine, LdT telbivudine, TDF tenofovir